Postoperative UFT Adjuvant and the Risk Factors for Recurrence in Renal Cell Carcinoma: A Long‐Term Follow‐Up Study

Abstract

Background: Radical nephrectomy is the standard therapy for low-stage renal cell carcinoma. However,

Evaluation of disease‐free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial‐level meta‐analysis

“…Sensitivity analyses included 2 additional studies that reported CSS instead of OS and provided similar results, with a modest R‐squared of 0.48 for the 5‐year DFS and OS/CSS correlation and an R‐squared of 0.54 for the treatments effects (Table ). Additional sensitivity analyses were performed to assess for a correlation with earlier endpoints of 3‐year and 4‐year DFS rates and 5‐year OS rates.…”

“… A total of 12 trials; the trials by Hinotsu et al and Naito et al were excluded because HRs could not be calculated due to incomplete information.…”

“…1). 3,4,[13][14][15][16][17][18][19][20][21][22][23] The ASSURE trial by Haas et al 3 was analyzed as 2 separate studies given that it contained 2 parallel, independent experimental treatment arms. The placebo group was downweighted (ie, only 50% of DFS events were counted) in all weighted analyses because it was included twice.…”

Adjuvant Therapy for Renal Cell Carcinoma

“…30 Another trial testing chemotherapy with adjuvant UFT (tegafur and uracil) was also unsuccessful. 31 Therefore, no treatment has demonstrated substantial and consistent benefit in the adjuvant setting for renal cell carcinoma, whether using immunotherapy, radiotherapy, hormonal therapy, or chemotherapy. Trials testing targeted therapies will be reviewed in the next section, because none of them have published final results and are still ongoing, some of them still accruing patients, and some others closed and with results pending.…”

Adjuvante Therapie des Nierenzellkarzinoms

“…Im Vergleich zu einem historischen Kollektiv ergab sich zwar ein signifikanter Unterschied (p < 0,01) hinsichtlich des 1-Jahres-Überlebens, jedoch wird dies auch von den Autoren nur als Argument für die Durchführung einer prospektiv randomisierten Studie gewertet. Wie beim metastasierenden Nierenzellkarzinom muû auch im adjuvanten Einsatz die Chemotherapie als weitgehend unwirksam betrachtet werden ( [17,19]; Tabelle 1).…”